The stock price of Silence Therapeutics Plc ADR (NASDAQ: SLN) has jumped by 6.58 compared to previous close of 5.24. Despite this, the company has seen a gain of 3.23% in its stock price over the last five trading days. businesswire.com reported 2025-06-12 that LONDON–(BUSINESS WIRE)—- $SLN #SenseofSilence–Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy. “The latest data presented at EHA today continue to demonstrate divesiran’s potential to maintain rapid and dur.
Is It Worth Investing in Silence Therapeutics Plc ADR (NASDAQ: SLN) Right Now?
SLN has 36-month beta value of 1.40. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLN is 37.61M, and currently, short sellers hold a 2.80% ratio of that float. The average trading volume of SLN on June 13, 2025 was 221.32K shares.
SLN’s Market Performance
SLN’s stock has seen a 3.23% increase for the week, with a 35.89% rise in the past month and a 37.56% gain in the past quarter. The volatility ratio for the week is 4.36%, and the volatility levels for the past 30 days are at 5.41% for Silence Therapeutics Plc ADR The simple moving average for the past 20 days is 7.13% for SLN’s stock, with a -37.44% simple moving average for the past 200 days.
Analysts’ Opinion of SLN
Many brokerage firms have already submitted their reports for SLN stocks, with Goldman repeating the rating for SLN by listing it as a “Sell.” The predicted price for SLN in the upcoming period, according to Goldman is $6 based on the research report published on February 11, 2025 of the current year 2025.
Jefferies gave a rating of “Buy” to SLN, setting the target price at $40 in the report published on September 03rd of the previous year.
SLN Trading at 38.74% from the 50-Day Moving Average
After a stumble in the market that brought SLN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.14% of loss for the given period.
Stock Fundamentals for SLN
Current profitability levels for the company are sitting at:
- -2.76 for the present operating margin
- 0.73 for the gross margin
The net margin for Silence Therapeutics Plc ADR stands at -2.17. The total capital return value is set at -0.35. Equity return is now at value -99.23, with -43.26 for asset returns.
Based on Silence Therapeutics Plc ADR (SLN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 1153.24. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 26.22.
Currently, EBITDA for the company is -48.99 million with net debt to EBITDA at 1.09. When we switch over and look at the enterprise to sales, we see a ratio of 7.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.81.
Conclusion
To put it simply, Silence Therapeutics Plc ADR (SLN) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
